A new drug called donanemab has shown promising results in slowing the progression of Alzheimer’s disease. In a clinical trial, patients who received donanemab experienced a 35.1% slower decline in cognitive function than those who received a placebo.
Donanemab is a monoclonal antibody that targets amyloid-beta plaques, which are thought to be a key driver of Alzheimer’s disease. The drug works by clearing these plaques from the brain, which can help to slow the progression of the disease.
The results of this trial are significant, as they provide the first real hope for a treatment that can slow or even prevent Alzheimer’s disease. Donanemab is currently being reviewed by the FDA, and it is expected to be approved for use in the United States later this year.
If you or a loved one is living with Alzheimer’s disease, this news is a major step forward. Donanemab is not a cure, but it could provide a way to slow the progression of the disease and improve quality of life.